Lisata Therapeutics, Inc. (LSTA)
Company Description
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.
Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease.
The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015.
The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022.
Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Country | United States |
Founded | 1980 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 25 |
CEO | Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. |
Contact Details
Address: 110 Allen Road, Second Floor Basking Ridge, New Jersey 07920 United States | |
Phone | 908-229-2590 |
Website | lisata.com |
Stock Details
Ticker Symbol | LSTA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000320017 |
ISIN Number | US1280583022 |
Employer ID | 22-2343568 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, Chief Executive Officer and Director |
Dr. Kristen K. Buck M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
James Nisco | Vice President of Finance and Treasury |
Tariq Imam | Vice President of Business Development and Operations and Corporate Counsel |
Gregory S. Berkin | Chief Information Officer |
John D. Menditto | Vice President of Investor Relations and Corporate Communications |
Gail Holler | Vice President of Human Resources |
Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | ARS | Filing |
Feb 29, 2024 | 10-K | Annual Report |
Feb 29, 2024 | 8-K | Current Report |
Nov 2, 2023 | 10-Q | Quarterly Report |
Nov 2, 2023 | 8-K | Current Report |
Aug 14, 2023 | 10-Q | Quarterly Report |
Aug 14, 2023 | 8-K | Current Report |
Jul 13, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
Jul 11, 2023 | 8-K | Current Report |
Jun 14, 2023 | 8-K | Current Report |